Director's Dealing • Sep 18, 2009
Director's Dealing
Open in ViewerOpens in native device viewer
Company Announcement
18 September 2009
Today, Bavarian Nordic has received information that persons holding managerial responsibilities and/or persons/companies closely associated with such have sold Bavarian Nordic shares.
Pursuant to Section § 28a of the Danish Act on Securities Trading, Bavarian Nordic A/S shall make public transactions of shares and related securities of Bavarian Nordic A/S by persons holding managerial responsibilities and/or persons/companies closely associated with such.
| Name | NeuroSearch A/S |
|---|---|
| Reason for transaction | Closely associated with Flemming Pedersen, member of the Board of Bavarian |
| Nordic A/S | |
| Issuer | Bavarian Nordic A/S |
| ID code/ISIN | DK0015998017 |
| Description | Shares |
| Transaction | Sale |
| Trading date | More – see below |
| Market | NASDAQ OMX Copenhagen |
| Total number | 100,102 |
| Total market value (DKK) | 23,967,541.42 |
Transactions per date:
| Trading date | Number of shares | Market value (DKK) |
|---|---|---|
| 28 August 2009 | 7,879 | 1,966,834.77 |
| 31 August 2009 | 6,090 | 1,440,528.60 |
| 1 September 2009 | 11,896 | 2,870,707.03 |
| 2 September 2009 | 2,500 | 600,000.00 |
| 3 September 2009 | 15,476 | 3,845,197.91 |
| 4 September 2009 | 3,014 | 764,136.41 |
| 7 September 2009 | 1,000 | 245,000.00 |
| 9 September 2009 | 270 | 64,800.00 |
| 10 September 2009 | 7,900 | 1,861,082.00 |
| 11 September 2009 | 350 | 82,250.00 |
| 14 September 2009 | 10,500 | 2,416,995.00 |
| 15 September 2009 | 9,300 | 2,187,164.70 |
| 16 September 2009 | 1,000 | 235,000.00 |
| 17 September 2009 | 22,927 | 5,387,845.00 |
Asger Aamund Chairman
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
Page 1 of 2 Company Announcement no. 23 / 2009
DK-3490 Kvistgaard Fax: +45 33 26 83 80 Denmark
This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline is focused in the three areas; biodefence, cancer and infectious diseases, and includes seven development programmes. Two programmes are ready for Phase III: IMVAMUNE®, a third-generation smallpox vaccine is being developed under a contract with the US government, and PROSTVAC™, a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute.
Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.
For more information please visit www.bavarian-nordic.com
Page 2 of 2 Company Announcement no. 23 / 2009
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.